Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer

Susan J. Ramus, Karim Elmasry, Zhiyuan Luo, Alex Gammerman, Karen Lu, Ayse Ayhan, Naveena Singh, W. Glenn McCluggage, Ian J. Jacobs, John C. Whittaker, Simon A. Gayther

Research output: Contribution to journalArticle

Abstract

Purpose: Patients with synchronous ovarian and endometrial cancers may represent cases of a single primary tumor with metastasis (SPM) or dual primary tumors (DP).The diagnosis given will influence the patient's treatment and prognosis. Currently, a diagnosis of SPM or DP is made using histologic criteria, which are frequently unable to make a definitive diagnosis. Experimental Design: In this study, we used genetic profiling to make a genetic diagnosis of SPM or DP in 90 patients with synchronous ovarian/endometrial cancers. We compared genetic diagnoses in these patients with the original histologic diagnoses and evaluated the clinical outcome in this series of patients based on their diagnoses. Results: Combining genetic and histologic approaches, we were able make a diagnosis in 88 of 90 cases, whereas histology alone was able to make a diagnosis in only 64 cases. Patients diagnosed with SPM had a significantly worse survival than patients with DP (P = 0.002). Patients in which both tumors were of endometrioid histology survived longer than patients of other histologic subtypes (P = 0.025), and patients diagnosed with SPM had a worse survival if the mode of spread was from ovary to endometrium rather than from endometrium to ovary (P = 0.019). Conclusions: Genetic analysis may represent a powerful tool for use in clinical practice for distinguishing between SPM and DP in patients with synchronous ovarian/endometrial cancer and predicting disease outcome. The data also suggest a hitherto uncharacterized level of heterogeneity in these cases, which, if accurately defined, could lead to improved treatment and survival.

Original languageEnglish (US)
Pages (from-to)5840-5848
Number of pages9
JournalClinical Cancer Research
Volume14
Issue number18
DOIs
StatePublished - Sep 15 2008
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Ovarian Neoplasms
Neoplasms
Endometrium
Survival
Ovary
Histology
Research Design
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ramus, S. J., Elmasry, K., Luo, Z., Gammerman, A., Lu, K., Ayhan, A., ... Gayther, S. A. (2008). Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. Clinical Cancer Research, 14(18), 5840-5848. https://doi.org/10.1158/1078-0432.CCR-08-0373

Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. / Ramus, Susan J.; Elmasry, Karim; Luo, Zhiyuan; Gammerman, Alex; Lu, Karen; Ayhan, Ayse; Singh, Naveena; Glenn McCluggage, W.; Jacobs, Ian J.; Whittaker, John C.; Gayther, Simon A.

In: Clinical Cancer Research, Vol. 14, No. 18, 15.09.2008, p. 5840-5848.

Research output: Contribution to journalArticle

Ramus, SJ, Elmasry, K, Luo, Z, Gammerman, A, Lu, K, Ayhan, A, Singh, N, Glenn McCluggage, W, Jacobs, IJ, Whittaker, JC & Gayther, SA 2008, 'Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer', Clinical Cancer Research, vol. 14, no. 18, pp. 5840-5848. https://doi.org/10.1158/1078-0432.CCR-08-0373
Ramus, Susan J. ; Elmasry, Karim ; Luo, Zhiyuan ; Gammerman, Alex ; Lu, Karen ; Ayhan, Ayse ; Singh, Naveena ; Glenn McCluggage, W. ; Jacobs, Ian J. ; Whittaker, John C. ; Gayther, Simon A. / Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 18. pp. 5840-5848.
@article{24c188badf20484d9ef59c466308f151,
title = "Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer",
abstract = "Purpose: Patients with synchronous ovarian and endometrial cancers may represent cases of a single primary tumor with metastasis (SPM) or dual primary tumors (DP).The diagnosis given will influence the patient's treatment and prognosis. Currently, a diagnosis of SPM or DP is made using histologic criteria, which are frequently unable to make a definitive diagnosis. Experimental Design: In this study, we used genetic profiling to make a genetic diagnosis of SPM or DP in 90 patients with synchronous ovarian/endometrial cancers. We compared genetic diagnoses in these patients with the original histologic diagnoses and evaluated the clinical outcome in this series of patients based on their diagnoses. Results: Combining genetic and histologic approaches, we were able make a diagnosis in 88 of 90 cases, whereas histology alone was able to make a diagnosis in only 64 cases. Patients diagnosed with SPM had a significantly worse survival than patients with DP (P = 0.002). Patients in which both tumors were of endometrioid histology survived longer than patients of other histologic subtypes (P = 0.025), and patients diagnosed with SPM had a worse survival if the mode of spread was from ovary to endometrium rather than from endometrium to ovary (P = 0.019). Conclusions: Genetic analysis may represent a powerful tool for use in clinical practice for distinguishing between SPM and DP in patients with synchronous ovarian/endometrial cancer and predicting disease outcome. The data also suggest a hitherto uncharacterized level of heterogeneity in these cases, which, if accurately defined, could lead to improved treatment and survival.",
author = "Ramus, {Susan J.} and Karim Elmasry and Zhiyuan Luo and Alex Gammerman and Karen Lu and Ayse Ayhan and Naveena Singh and {Glenn McCluggage}, W. and Jacobs, {Ian J.} and Whittaker, {John C.} and Gayther, {Simon A.}",
year = "2008",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-08-0373",
language = "English (US)",
volume = "14",
pages = "5840--5848",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer

AU - Ramus, Susan J.

AU - Elmasry, Karim

AU - Luo, Zhiyuan

AU - Gammerman, Alex

AU - Lu, Karen

AU - Ayhan, Ayse

AU - Singh, Naveena

AU - Glenn McCluggage, W.

AU - Jacobs, Ian J.

AU - Whittaker, John C.

AU - Gayther, Simon A.

PY - 2008/9/15

Y1 - 2008/9/15

N2 - Purpose: Patients with synchronous ovarian and endometrial cancers may represent cases of a single primary tumor with metastasis (SPM) or dual primary tumors (DP).The diagnosis given will influence the patient's treatment and prognosis. Currently, a diagnosis of SPM or DP is made using histologic criteria, which are frequently unable to make a definitive diagnosis. Experimental Design: In this study, we used genetic profiling to make a genetic diagnosis of SPM or DP in 90 patients with synchronous ovarian/endometrial cancers. We compared genetic diagnoses in these patients with the original histologic diagnoses and evaluated the clinical outcome in this series of patients based on their diagnoses. Results: Combining genetic and histologic approaches, we were able make a diagnosis in 88 of 90 cases, whereas histology alone was able to make a diagnosis in only 64 cases. Patients diagnosed with SPM had a significantly worse survival than patients with DP (P = 0.002). Patients in which both tumors were of endometrioid histology survived longer than patients of other histologic subtypes (P = 0.025), and patients diagnosed with SPM had a worse survival if the mode of spread was from ovary to endometrium rather than from endometrium to ovary (P = 0.019). Conclusions: Genetic analysis may represent a powerful tool for use in clinical practice for distinguishing between SPM and DP in patients with synchronous ovarian/endometrial cancer and predicting disease outcome. The data also suggest a hitherto uncharacterized level of heterogeneity in these cases, which, if accurately defined, could lead to improved treatment and survival.

AB - Purpose: Patients with synchronous ovarian and endometrial cancers may represent cases of a single primary tumor with metastasis (SPM) or dual primary tumors (DP).The diagnosis given will influence the patient's treatment and prognosis. Currently, a diagnosis of SPM or DP is made using histologic criteria, which are frequently unable to make a definitive diagnosis. Experimental Design: In this study, we used genetic profiling to make a genetic diagnosis of SPM or DP in 90 patients with synchronous ovarian/endometrial cancers. We compared genetic diagnoses in these patients with the original histologic diagnoses and evaluated the clinical outcome in this series of patients based on their diagnoses. Results: Combining genetic and histologic approaches, we were able make a diagnosis in 88 of 90 cases, whereas histology alone was able to make a diagnosis in only 64 cases. Patients diagnosed with SPM had a significantly worse survival than patients with DP (P = 0.002). Patients in which both tumors were of endometrioid histology survived longer than patients of other histologic subtypes (P = 0.025), and patients diagnosed with SPM had a worse survival if the mode of spread was from ovary to endometrium rather than from endometrium to ovary (P = 0.019). Conclusions: Genetic analysis may represent a powerful tool for use in clinical practice for distinguishing between SPM and DP in patients with synchronous ovarian/endometrial cancer and predicting disease outcome. The data also suggest a hitherto uncharacterized level of heterogeneity in these cases, which, if accurately defined, could lead to improved treatment and survival.

UR - http://www.scopus.com/inward/record.url?scp=53249086541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249086541&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-0373

DO - 10.1158/1078-0432.CCR-08-0373

M3 - Article

C2 - 18794095

AN - SCOPUS:53249086541

VL - 14

SP - 5840

EP - 5848

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -